Share |
Press Releases 2011
December 22, 2011 at 2:00 pm

Verisante Starts FDA Approval Process and Provides Operational Update


  2011 A BREAKTHROUGH YEAR FOR VERISANTE AURA  VANCOUVER, BRITISH COLUMBIA - Verisante Technology, Inc. (TSX-V: VRS, OTCQX: VRSEF, Frankfurt: V3T) (the “Company” or “Verisante”), a leader in skin cancer detection technology, has begun the process to obtain US Food and Drug Administration (FDA) approval for Verisante Aura....

Full story

December 19, 2011 at 1:30 pm

Verisante Obtains Australian Approval


VERISANTE AURA RECEIVES ARTG LISTING BY THE THERAPEUTIC GOODS ADMINISTRATION OF AUSTRALIA VANCOUVER, BRITISH COLUMBIA - Verisante Technology, Inc. (TSX-V: VRS, OTCQX: VRSEF, Frankfurt: V3T) (the “Company” or “Verisante”), a leader in skin cancer detection technology, announced today that it has received regulatory approval to market and sell the...

Full story

November 16, 2011 at 4:00 pm

Popular Science Honors Innovative Verisante Aura™ Skin Cancer Detection Device with “Best of What’s New” Award


VANCOUVER, BRITISH COLUMBIA - Verisante Technology, Inc. (TSX-V: VRS, OTCQX: VRSEF, Frankfurt: V3T) (the “Company” or “Verisante”), a leader in cancer imaging technology, announced today that the editors of Popular Science magazine have named Verisante’s Aura™ device for skin cancer detection as a top technology innovation of 2011, receiving one...

Full story

November 9, 2011 at 2:00 pm

CE Mark for Verisante Aura™ Opens Doors to Massive European Market


APPROVAL WILL PROVIDE THE INNOVATIVE, LIFE-SAVING SKIN CANCER DETECTOR ACCESS TO A 
$78 BILLION EUROPEAN MEDICAL DEVICE MARKET AND 27 EU MEMBER STATES VANCOUVER, BRITISH COLUMBIA - Verisante Technology, Inc. (TSX-V: VRS, OTCQX: VRSEF, Frankfurt: V3T) (the “Company” or “Verisante”), a leader in cancer imaging technology, announced today that...

Full story

October 19, 2011 at 3:38 pm

Health Canada Approval For Verisante Aura™ Marks Milestone In Skin Cancer Detection


INNOVATIVE MEDICAL DEVICE THAT HELPS SAVE LIVES, SAVE MONEY AND PROVIDE QUICK, ACCURATE RESULTS READIES FOR LAUNCH VANCOUVER, BRITISH COLUMBIA - Verisante Technology, Inc. (TSX-V: VRS, OTCQX: VRSEF, Frankfurt: V3T) (the “Company” or “Verisante”), a leader in cancer imaging technology, announced today that it has obtained a licence from...

Full story

October 6, 2011 at 2:00 pm

Verisante Issues Update on Regulatory Milestones


FILES WITH HEALTH CANADA AND READIES APPLICATION FOR CE MARK VANCOUVER, BRITISH COLUMBIA - Verisante Technology, Inc. (TSX-V: VRS, OTCQX: VRSEF, Frankfurt: V3T) (the “Company” or “Verisante”), a leader in cancer imaging technology, announced today that it has filed an application with Health Canada for a Class II Medical...

Full story

August 23, 2011 at 2:00 pm

Verisante to Attend Conferences and Trade Shows in Australia, China and Europe


VERISANTE AURA™, THE EARLY SKIN CANCER DETECTION DEVICE, WILL BE FEATURED THIS FALL IN A TELEVISION SPECIAL “SKIN DEEP IN THE NHS” ON BBC, ITV AND SKY TV Vancouver, Canada: Verisante Technology, Inc. (TSX-V: VRS, OTCQX: VRSEF, Franfurt:V3T) (the “Company” or “Verisante”), a leader in cancer imaging technology, announced today...

Full story

August 3, 2011 at 2:00 pm

Verisante Engages Manufacturing Partner And Provides Operational Update For Verisante Aura™ Device For Skin Cancer Detection


Verisante Currently Exhibiting At The American Academy Of Dermatology Summer Meeting In New York From August 3-7 Vancouver, Canada: Verisante Technology, Inc. (TSX-V: VRS, OTCQX: VRSEF, Frankfurt:V3T) (the “Company” or “Verisante”), a leader in cancer imaging technology, announced today that it has engaged StarFish Medical Inc. to provide engineering...

Full story

July 28, 2011 at 2:00 pm

Verisante Obtains ISO Certification Of Quality Management System For Medical Device Manufacturing


Vancouver, Canada: Verisante Technology, Inc. (TSX-V: VRS, OTCQX: VRSEF, Frankfurt:V3T) (the "Company" or "Verisante"), a leader in cancer imaging technology, announced today that it has successfully completed the certification process for ISO 13485:2003, an internationally recognized quality management standard.   The certification is a confirmation of the Company's ability to design...

Full story

July 21, 2011 at 7:30 pm

Verisante Joins Frankfurt Stock Exchange


Vancouver, Canada: Verisante Technology, Inc. (TSX-V: VRS, OTCQX: VRSEF, Frankfurt: V3T) (the “Company” or “Verisante”), a leader in cancer imaging technology, announced today that the Company has begun trading on the Frankfurt Stock Exchange, one of the world’s largest trading centres for securities.  "Verisante is steadily moving towards obtaining...

Full story

July 20, 2011 at 1:30 pm

Verisante Unveils Industrial Design of Verisante Aura


Vancouver, Canada: Verisante Technology, Inc. (TSX-V: VRS, OTCQX: VRSEF) (the “Company” or “Verisante”), a leader in cancer imaging technology, is pleased to unveil the industrial design renderings of the Company’s Verisante Aura™ device for the early detection of skin cancer. “The design of Verisante’s Aura™ is meant to mirror the...

Full story

July 18, 2011 at 3:31 pm

Unaware of Any Material Change


At the request of IIROC Vancouver, Canada: Verisante Technology, Inc. (TSX-V: VRS, OTCQX: VRSEF) (the “Company” or “Verisante”), a leader in cancer imaging technology, wishes to confirm that is it unaware of any material change in the Company's operations that would account for the recent increase in market activity. ...

Full story

July 12, 2011 at 2:00 pm

Verisante Enters Licensing Agreement For Multi Spectral Imaging Technology To Detect Skin Cancer And Oral Cancer


Vancouver, Canada: Verisante Technology, Inc. (TSX-V: VRS, OTCQX: VRSEF) (the "Company" or "Verisante"), a leader in cancer imaging technology, is pleased to announce that it has entered into an agreement to license the exclusive world-wide rights for a novel rapid multi-spectral imaging cancer detection technology with the inventors, Dr. Haishan...

Full story

July 6, 2011 at 2:00 pm

Verisante Technology Inc. Announces Pilot Study Results for Lung Cancer Detection System


Vancouver, Canada: Verisante Technology, Inc. (TSX-V: VRS; OTCQX: VRSEF) (the “Company” or “Verisante”) is pleased to announce that the results of a pilot study on lung cancer detection will be published in the prestigious Journal of Thoracic Oncology in July.  The results of the pilot study indicate that the Company’s...

Full story

June 13, 2011 at 2:00 pm

Verisante Enters into Asset Purchase Agreement with Perceptronix Medical


Verisante Technology, Inc. (TSX-V: VRS, OTCQX: VRSEF) (the “Company” or Verisante”) announced today that the Company has entered into an Asset Purchase Agreement with Perceptronix Medical Inc. (“PMI”). Under the terms of the Agreement, Verisante has purchased all rights to the ClearVu™ and ClearVu Elite™ endoscopy systems for early lung...

Full story

May 26, 2011 at 2:00 pm

Verisante Technology Inc., Lists on the OTCQX; Completes Stage 1 Audit Towards ISO Certification


Vancouver, Canada: Verisante Technology, Inc. (TSX-V: VRS, OTCQX: VRSEF) (the “Company” or “Verisante”) announced today that the Company will begin trading on the OTCQX International Tier as of the market opening on Thursday, May 26, 2011.  The OTCQX International is the premier tier of the US OTC market, home to...

Full story

May 9, 2011 at 2:00 pm

Verisante Pursues Listings on the OTCQX and Frankfurt Stock Exchange


New listings would broaden access for American and European investors interested in innovative device for the early detection of skin cancer Vancouver, Canada: Verisante Technology, Inc. (TSX-V: VRS, PINKSHEETS: VRSEF) (the “Company” or “Verisante”) announced today that the Company is pursuing listings on both the OTCQX and the Frankfurt...

Full story

May 2, 2011 at 2:02 pm

CIHR Awards Grant Towards The Commercialization of Revolutionary Verisante Aura Skin Cancer Detector; Opens Market


Vancouver, Canada: Verisante Technology, Inc. (TSX-V: VRS, PINKSHEETS: VRSEF) (the “Company” or “Verisante”) announced today that the Canadian Institutes of Health Research (“CIHR”) has approved a grant application by the BC Cancer Agency to develop the Verisante Aura™ skin cancer detection device based on matching funds from the Company.   ...

Full story

April 18, 2011 at 2:00 pm

Skin Cancer Detection Company Completes $5 million private placement; Industrial space expanded, analysis of clinical trial data


Vancouver, Canada: Verisante Technology, Inc. (TSX-V: VRS, PINKSHEETS: VRSEF) (the “Company” or “Verisante”) announced today that it has completed a previously announced private placement of 12,500,000 units (“Units”) at a price of $0.40 per Unit for gross proceeds of $5,000,000. Each Unit consists of one common share of the...

Full story

March 19, 2011 at 12:06 am

Verisante Announces Non Brokered Private Placement


Vancouver, Canada: Verisante Technology, Inc. (TSX-V: VRS, PINKSHEETS: VRSEF) (the “Company” or “Verisante”) announces that it intends to complete a non-brokered private placement of up to 12,500,000 units at a price of $0.40 per unit for proceeds of up to $5,000,000 (the “Offering”).  Each unit will comprise of one common...

Full story

February 15, 2011 at 2:00 pm

Verisante Featured on Business Television (BTV), Announces Conference Attendance


Vancouver, Canada: Verisante Technology, Inc. (TSX-V: VRS, OTC: VRSEF) (the “Company” or “Verisante”) announces that the Company will be featured on Business Television (BTV) to air on February 19 and 20, 2011. BTV, a half-hour business program, has been profiling innovative companies in North America every week for the past...

Full story

February 7, 2011 at 3:00 pm

Zacks Investment Research Initiates Coverage on Verisante Technology with Outperform Rating


Vancouver, Canada: Verisante Technology, Inc. (TSX-V: VRS, OTC: VRSEF) (the “Company” or “Verisante”) announced today that Zacks Investment Research has initiated coverage of the Company. Zacks, which provides independent investment research to individual and institutional investors, has released a comprehensive report that describes Verisante and its proprietary cancer-detection technology in...

Full story

February 1, 2011 at 3:47 pm

Verisante Completes Private Placement, Announces Attendance at the American Academy of Dermatology Meeting


Vancouver, Canada: Verisante Technology, Inc. (TSX-V: VRS) (the “Company” or “Verisante”) announced today that it has completed a private placement of 4,000,000 units (“Units”) at a price of $0.25 per Unit for gross proceeds of $1,000,000. Each Unit consists of one common share of the Company and one common...

Full story

January 25, 2011 at 7:53 pm

Verisante Announces US Stock Symbol and Participation with Standard & Poors Market Access Program


Vancouver, Canada: Verisante Technology, Inc. (TSX-V: VRS, OTC: VRSEF.PK) (the “Company” or “Verisante”) announced today that its Company information will be made available via Standard & Poor's Market Access Program, an information distribution service that enables subscribing publicly traded companies to have their company information disseminated to users of...

Full story

January 17, 2011 at 7:43 pm

T-Ray Science Announces Name Change


Vancouver, Canada: T-Ray Science, Inc. (TSX-V: THZ) (the “Company” or “T-Ray”) announces that, at a Special Meeting of Shareholders held on January 13, 2011, shareholders approved a change of the name of the Company to Verisante Technology, Inc. (“Verisante”). Concurrently, the Company’s URL has changed to http://www.verisante.com. The common shares...

Full story

January 10, 2011 at 9:05 pm

T-Ray Science Announces Key Milestones Toward Commercialization


UBC Research Agreement, Health Canada Ruling and Lease for  Manufacturing Space Secured for Innovative Cancer Detection Device Vancouver, Canada: T-Ray Science, Inc. (TSX-V: THZ) (the “Company” or “T-Ray”) announced  a number of milestones today that will lead toward the commercialization of the Company’s cancer detection technology for skin cancer....

Full story

  Back to top